Lack of association between C385A functional polymorphism of the fatty acid amide hydrolase gene and polycystic ovary syndrome

V. K. Grolmusz, B. Stenczer, T. Fekete, G. Szendei, A. Patócs, K. Rácz, P. Reismann

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Introduction: The endocannabinoid system contributes to the regulation of appetite, food intake and energy balance. Fatty acid amide hydrolase is responsible for degradating anandamide, a key messenger of the endocannabinoid system. C385A is a common, functionally active genetic polymorphism of the gene encoding fatty acid amide hydrolase and has been associated with overweight and obesity. Our aim was to establish whether single nucleotide polymorphism C385A has an association with polycystic ovary syndrome or its clinical features. Materials and Methods: A monocentric pilot study was performed on 63 patients with polycystic ovary syndrome and 67 healthy control subjects. Anthropometric parameters and laboratory data were acquired from subjects. The alleles of the polymorphism were detected using polymerase chain reaction and subsequent cleavage by Eco130I (StyI) restriction endonuclease verified by direct DNA sequencing. Results: No difference was found in minor allele frequency between patient and control groups. Those patients, carrying the C385A polymorphism were associated with higher free thyroxine hormone levels. In the control group, carriers of the polymorphism had significantly lower insulin levels. Discussion and Conclusions: Our data indicate that the C385A polymorphism of the fatty acid amide hydrolase gene is not a genetic susceptibility factor for the development of polycystic ovary syndrome. However, the polymorphism might have a role in influencing the synthesis or metabolism of different hormones including thyroxin and insulin.

Original languageEnglish
Pages (from-to)338-342
Number of pages5
JournalExperimental and Clinical Endocrinology and Diabetes
Volume121
Issue number6
DOIs
Publication statusPublished - 2013

Fingerprint

Polycystic Ovary Syndrome
Endocannabinoids
Thyroxine
Hormones
Insulin
Genes
Appetite Regulation
Control Groups
DNA Restriction Enzymes
Genetic Polymorphisms
Genetic Predisposition to Disease
DNA Sequence Analysis
Gene Frequency
Single Nucleotide Polymorphism
Healthy Volunteers
Obesity
Alleles
Polymerase Chain Reaction
fatty-acid amide hydrolase

Keywords

  • endocannabinoid system
  • FAAH
  • PCOS
  • SNP

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Lack of association between C385A functional polymorphism of the fatty acid amide hydrolase gene and polycystic ovary syndrome. / Grolmusz, V. K.; Stenczer, B.; Fekete, T.; Szendei, G.; Patócs, A.; Rácz, K.; Reismann, P.

In: Experimental and Clinical Endocrinology and Diabetes, Vol. 121, No. 6, 2013, p. 338-342.

Research output: Contribution to journalArticle

@article{52e7661d6de34072b91fee90995b669e,
title = "Lack of association between C385A functional polymorphism of the fatty acid amide hydrolase gene and polycystic ovary syndrome",
abstract = "Introduction: The endocannabinoid system contributes to the regulation of appetite, food intake and energy balance. Fatty acid amide hydrolase is responsible for degradating anandamide, a key messenger of the endocannabinoid system. C385A is a common, functionally active genetic polymorphism of the gene encoding fatty acid amide hydrolase and has been associated with overweight and obesity. Our aim was to establish whether single nucleotide polymorphism C385A has an association with polycystic ovary syndrome or its clinical features. Materials and Methods: A monocentric pilot study was performed on 63 patients with polycystic ovary syndrome and 67 healthy control subjects. Anthropometric parameters and laboratory data were acquired from subjects. The alleles of the polymorphism were detected using polymerase chain reaction and subsequent cleavage by Eco130I (StyI) restriction endonuclease verified by direct DNA sequencing. Results: No difference was found in minor allele frequency between patient and control groups. Those patients, carrying the C385A polymorphism were associated with higher free thyroxine hormone levels. In the control group, carriers of the polymorphism had significantly lower insulin levels. Discussion and Conclusions: Our data indicate that the C385A polymorphism of the fatty acid amide hydrolase gene is not a genetic susceptibility factor for the development of polycystic ovary syndrome. However, the polymorphism might have a role in influencing the synthesis or metabolism of different hormones including thyroxin and insulin.",
keywords = "endocannabinoid system, FAAH, PCOS, SNP",
author = "Grolmusz, {V. K.} and B. Stenczer and T. Fekete and G. Szendei and A. Pat{\'o}cs and K. R{\'a}cz and P. Reismann",
year = "2013",
doi = "10.1055/s-0033-1337941",
language = "English",
volume = "121",
pages = "338--342",
journal = "Experimental and Clinical Endocrinology and Diabetes",
issn = "0947-7349",
publisher = "Thieme",
number = "6",

}

TY - JOUR

T1 - Lack of association between C385A functional polymorphism of the fatty acid amide hydrolase gene and polycystic ovary syndrome

AU - Grolmusz, V. K.

AU - Stenczer, B.

AU - Fekete, T.

AU - Szendei, G.

AU - Patócs, A.

AU - Rácz, K.

AU - Reismann, P.

PY - 2013

Y1 - 2013

N2 - Introduction: The endocannabinoid system contributes to the regulation of appetite, food intake and energy balance. Fatty acid amide hydrolase is responsible for degradating anandamide, a key messenger of the endocannabinoid system. C385A is a common, functionally active genetic polymorphism of the gene encoding fatty acid amide hydrolase and has been associated with overweight and obesity. Our aim was to establish whether single nucleotide polymorphism C385A has an association with polycystic ovary syndrome or its clinical features. Materials and Methods: A monocentric pilot study was performed on 63 patients with polycystic ovary syndrome and 67 healthy control subjects. Anthropometric parameters and laboratory data were acquired from subjects. The alleles of the polymorphism were detected using polymerase chain reaction and subsequent cleavage by Eco130I (StyI) restriction endonuclease verified by direct DNA sequencing. Results: No difference was found in minor allele frequency between patient and control groups. Those patients, carrying the C385A polymorphism were associated with higher free thyroxine hormone levels. In the control group, carriers of the polymorphism had significantly lower insulin levels. Discussion and Conclusions: Our data indicate that the C385A polymorphism of the fatty acid amide hydrolase gene is not a genetic susceptibility factor for the development of polycystic ovary syndrome. However, the polymorphism might have a role in influencing the synthesis or metabolism of different hormones including thyroxin and insulin.

AB - Introduction: The endocannabinoid system contributes to the regulation of appetite, food intake and energy balance. Fatty acid amide hydrolase is responsible for degradating anandamide, a key messenger of the endocannabinoid system. C385A is a common, functionally active genetic polymorphism of the gene encoding fatty acid amide hydrolase and has been associated with overweight and obesity. Our aim was to establish whether single nucleotide polymorphism C385A has an association with polycystic ovary syndrome or its clinical features. Materials and Methods: A monocentric pilot study was performed on 63 patients with polycystic ovary syndrome and 67 healthy control subjects. Anthropometric parameters and laboratory data were acquired from subjects. The alleles of the polymorphism were detected using polymerase chain reaction and subsequent cleavage by Eco130I (StyI) restriction endonuclease verified by direct DNA sequencing. Results: No difference was found in minor allele frequency between patient and control groups. Those patients, carrying the C385A polymorphism were associated with higher free thyroxine hormone levels. In the control group, carriers of the polymorphism had significantly lower insulin levels. Discussion and Conclusions: Our data indicate that the C385A polymorphism of the fatty acid amide hydrolase gene is not a genetic susceptibility factor for the development of polycystic ovary syndrome. However, the polymorphism might have a role in influencing the synthesis or metabolism of different hormones including thyroxin and insulin.

KW - endocannabinoid system

KW - FAAH

KW - PCOS

KW - SNP

UR - http://www.scopus.com/inward/record.url?scp=84879113068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879113068&partnerID=8YFLogxK

U2 - 10.1055/s-0033-1337941

DO - 10.1055/s-0033-1337941

M3 - Article

C2 - 23616186

AN - SCOPUS:84879113068

VL - 121

SP - 338

EP - 342

JO - Experimental and Clinical Endocrinology and Diabetes

JF - Experimental and Clinical Endocrinology and Diabetes

SN - 0947-7349

IS - 6

ER -